Abstract

Treatment with currently available antidepressants, which act on catechol and monoamine neurotransmitters, has yielded variable outcomes, leading to studies of medications (e.g., ketamine, tianeptine) acting via other mechanisms, such as glutaminergic pathways. These investigators studied the role of β-catenin pathways in genetic–environmental interactions that produce depressive behaviors in mice; β-catenin is a …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call